CLDX FINANCIAL STATEMENTS

Celldex Therapeutics Inc — balance sheet, income statement and cash flow trends

CLDXCelldex Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue820 K $-89.2%

Gross Profit-117.2 M $—

Operating Income-309.1 M $—

EBITDA-280.3 M $—

Net Income-283.7 M $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
CLDX	-89.2%	-14,287.9%	-34,185.6%	-34,596.2%
TLX	56.3%	50.8%	3.0%	-0.9%
MSB	410.4%	-32.0%	-76.6%	-115.3%
CSL	4.8%	48.6%	32.8%	9.2%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
CLDX	-89.2%	-14,287.9%	-34,185.6%	-34,596.2%
COGT	-100.0%	—	—	—
TRVI	-100.0%	—	—	—
NRIX	27.2%	-139.4%	-382.1%	-411.4%
VCEL	22.4%	74.8%	12.1%	7.3%
KOD	-100.0%	—	—	—
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity456.2 M $89%
Current Liabilities51.5 M $10%
Long-term Liabilities3.6 M $1%

Key Figures

YoY change

Total Assets511.3 M $-30.9%

Total Liabilities55 M $+50.8%

Total Equity456.2 M $-35.1%

Cash & ST Investments451.5 M $-32.9%

Total Debt1.9 M $-44.3%

Net Debt-33.8 M $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
CLDX	8.92	0.4%	1.60	89.2%
TLX	1.43	112.3%	13.13	35.1%
MSB	—	—	—	—
CSL	2.57	67.4%	2.22	49.2%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
CLDX	8.92	0.4%	1.60	89.2%
COGT	15.14	39.3%	1.79	67.3%
TRVI	24.75	0.4%	3.76	95.8%
NRIX	6.01	12.2%	1.76	75.6%
VCEL	5.18	26.5%	-1.44	73.4%
KOD	3.54	139.2%	0.07	36.6%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-222.2 M $—

Capital Expenditures3.8 M $+98.6%

Free Cash Flow-226 M $—

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
CLDX	-27,092.8%	-27,556.2%	463.4%	78.3%
TLX	-2.2%	-6.3%	4.1%	243.1%
MSB	-87.7%	-90.0%	2.3%	76.1%
CSL	24.0%	20.3%	3.7%	261.5%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
CLDX	-27,092.8%	-27,556.2%	463.4%	78.3%
COGT	—	—	—	80.4%
TRVI	—	—	—	99.3%
NRIX	-362.6%	-378.7%	16.1%	88.2%
VCEL	21.1%	19.8%	11.1%	287.5%
KOD	—	—	—	63.7%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on CLDX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.